An off-the-shelf, small diameter tissue engineered vascular graft (TEVG) would be transformative to surgeons in multiple subspecialties. Herein, the results of a small diameter (ID ≈ 1 mm) vascular graft constructed from resorbable, amino acid-based poly(ester urea) (PEU) are reported. Electrospun PEU grafts of two different wall thicknesses (type A: 250 μm; type B: 350 μm) are implanted as abdominal infra-renal aortic grafts in a severe combined immune deficient/beige mouse model and evaluated for vessel remodeling over one year. Significantly, the small diameter TEVG does not rupture or lead to acute thrombogenic events during the intervals tested. The pilot TEVG in vivo shows long-term patency and extensive tissue remodeling with type A grafts. Extensive tissue remodeling in type A grafts leads to the development of well-circumscribed neovessels with an endothelial inner lining, a neointima containing smooth muscle cells. However, due to slow degradation of the PEU scaffold materials in vivo, the grafts remain after one year. The type B grafts, which have 350 μm thick walls, experience occlusion over the one year interval due to intimal hyperplasia. This study affords significant findings that will guide the design of future generations of small diameter vascular grafts.
utility of these synthetic material has been limited to vascular grafts (>5 mm ID) in areas where the blood flow rate is high and resistance is low. Historically, when applied to small diameter (<5 mm ID) vessel replacements, e.g., coronary bypass surgery, both ePTFE and Dacron show high failure rates due to acute thrombus formation, and chronic anastomotic (excessive tissue formation in adjacent arterial tissue) and/or intimal (excessive tissue ingrowth through the graft wall) hyperplasia. [7] [8] [9] [10] These limitations sig nificantly reduce the availability of these approaches to many patient populations who need them. Therefore, development of clinically acceptable small diameter vas cular grafts as an alternative to autologous artery or vein substitutes is of significant clinical interest.
Tissue engineered vascular grafts (TEVGs) using resorbable polymers is one of the most promising approaches to address clinical challenges in small diameter vessels. Bioresorb able grafts are analogous to biostable grafts, such as those made of ePTFE or Dacron except one major difference: the poly mers used are degradable and allow the neoartery to remodel in vivo. [3, 10, 11] Ideally, the implanted graft should progressively degrade in a timeframe that allows mechanical compensation by extracellular matrix (ECM) deposition and remodeling asso ciated with the natural arterial regeneration process. [12] This approach combines the advantages of a synthetic graft (e.g., availability, manufacturing, sterilization, storage) and the excel lent longterm performance of natural tissues (e.g., diminished risk of immune rejection, optimal biological and structural properties). [13] Over the years, substantial work by many groups have uti lized synthetic degradable polymers, including poly(lactic acid) (PLA), [14] [15] [16] poly(glycolic acid) (PGA), [17] [18] [19] [20] poly(caprolactone) (PCL), [12, [21] [22] [23] poly(glycerol sebacate) (PGS), [24] [25] [26] [27] poly(ester amide)s, [28] [29] [30] [31] polyurethanes, [13, 32, 33] natural polymers (e.g., col lagen, [34, 35] silk fibroin [36] [37] [38] ), and their respective copolymers or blends, [39] [40] [41] [42] [43] for tissue engineered small diameter vas cular grafts. The Breuer and Shinoka lab developed the first tissue engineered small diameter vascular graft to be used in humans. [44] [45] [46] This vascular graft is created by seeding autolo gous bone marrow derived mononuclear cells (BMMCs) onto biodegradable PLLA/PCLA tubular scaffolds and forms a living
Introduction
Cardiovascular diseases resulting from arteriosclerosis are the leading cause of death globally. [1] In the United States, more than 500 000 coronary bypass surgeries are performed each year. [2, 3] Autologous grafts from the saphenous vein or the internal mammary artery are the gold standard for arterial bypass surgery. [4, 5] However, the procedures have drawbacks including limited tissue availability, the need for additional sur geries, donor site morbidity, and an ≈30% 10year failure rate. [6] Synthetic vascular grafts, such as those made of expanded pol ytetrafluoroethylene (ePTFE) and woven or knitted polyethylene terephthalate (PET, Dacron) have been clinically available for quite some time. While clearly innovative solutions, the clinical vascular conduit with the ability to grow, repair, and remodel. The first human clinical trial evaluating the use of this TEVG followed. [47] [48] [49] Initial results demonstrated an excellent safety profile for the TEVG, again with the additional benefit of growth potential for use in children where somatic overgrowth of nondegradable material is a significant barrier to progress in the field. Moving forward, the same group fabricated a cellfree TEVG for arterial circulation constructed from PCL and rein forced by PLA fiber mesh to enhance cell migration into the scaffolds. [50] The process of vessel remodeling of the TEVG in a mouse abdominal infrarenal aorta model during a 12 month period demonstrated organized neotissue formation. However, due to the uncoordinated scaffold degradation time with new vessel remodeling and the acidic scaffold degradation byprod ucts, we speculate that most grafts experienced aneurysmal changes and prolonged inflammation. In addition, intimal hyperplasia and graft rupture resulting from mechanical mis match between implanted grafts and native vessels, acute clot ting, and limited tissue regeneration are believed to be respon sible for the graft failures. [3, 10] New biodegradable polymers with tunable degradation rate and mechanical properties that can match the remodeling process of a bioresorbable vascular graft in situ are very desirable.
Amino acid based poly(ester urea)s (PEUs) were developed as a new class of bioresorbable polymers. [51] [52] [53] In 1997, Kat sarava and coworkers published a synthesis of PEUs via active polycondensation without using diisocyanates. [54] By using a modified version of the process, we have synthesized a series of amino acid based PEUs that showed tunable degradation properties with nontoxic byproducts. [55] [56] [57] [58] [59] [60] [61] The mechanical properties, in vitro and in vivo, demonstrated that these mate rials are suitable candidates for vascular tissue engineering. [61] In this study, PEU derived from lleucine and 1,10decanediol, named as poly(1LEU10), was used to fabricate porous grafts with very small diameter (ID ≈ 1 mm). Electrospinning was used to fabricate the 1 mm inner diameter grafts as it affords the reliable and consistent generation of fibrous structure that resembles extracellular matrix (ECM) in the native vessel wall with no residual solvent. The structures also support cell infiltration and cellularization of the grafts. [62] [63] [64] [65] Small diam eter (ID ≈ 1 mm) graft tubes with two different wall thick nesses (i.e., type A: 250 μm; type B: 350 μm) were fabricated. Biomechanical properties of the grafts were measured in vitro. The grafts were then studied in vivo in a severe com bined immune deficient (SCID)/beige (Bg) mouse abdominal infrarenal aorta replacement model for longterm evaluation. This pilot study aims to develop a cellfree resorbable small diameter vascular graft based on electrospun PEU and assess the utility of the TEVG in vivo.
Results and Discussion

Polymer Synthesis and Characterization
The PEU polymer was synthesized from the amino acid lleu cine, 1,10decanediol, and triphosgene using an interfacial polymerization as described in Figure 1 . [56, 58] The chemical structures of the monomer and polymer were confirmed by 1 H NMR and 13 C NMR spectroscopy (Figures S1 and S2, Supporting Information). The molecular mass, molecular mass distribution, and thermal properties of the polymer were measured by size exclusion chromatography (SEC), differential scanning calorim etry (DSC), and thermogravimetric analysis (TGA). The data are listed in Table 1 . High molecular mass PEU (M w > 100 kDa) was synthesized using interfacial polymerization. Generally, high molecular mass PEU polymers are required to reproducibly generate fiber or films for biomaterial scaffolds. Furthermore, the degradation temperature (T d , 273 °C) of the poly(1LEU10) material is significantly higher than the glass transition tem perature (T g , 30 °C), indicating that this material can be melt processed with limited degradation. These characteristics afford high temperature processing techniques such as injection molding and melt processing to be used to process the PEU polymers in addition to electrospinning.
Scaffold Characterization
Electrospinning conditions (solution concentration, flow rate, voltage levels, etc.) were optimized in order to obtain uniform beadfree nanofiber morphology prior to collection on a rotating mandrel used for graft fabrication. TEVG scaffolds obtained were cut into 1 mm thick cross sections and imaged on a field emission scanning electron microscopy (FESEM; JSM7401F, JEOL Ltd., Japan). Fiber diameters at the outer surface and wall thickness were measured using high and lowmagnification SEM images. Figure 2a shows the gross appearance of the whole electrospun graft. The fabricated grafts were generally 3 cm in length with an inner diameter of ≈1 mm. Figure 2b shows a tilted view of the graft tube at lowmagnification SEM. 1-LEU-10) ). In the first step, 1 e.q. of 1,10-decanediol is condensed with 2.3 e.q. of l-leucine to yield the monomer. During this step, the amino acids are protonated with p-toluene sulfonic acid to prevent amidation reactions. In the second step, interfacial polycondensation of monomers with triphosgene yields PEU homopolymer. Table 1 . Characterization data summary for PEU polymer.
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At low magnification, the graft has a round tubular structure. At higher magnification, the surface exhibits a consistent fiber structure (Figure 2c ), and at the edge of the graft, cross sections of the fibers appear to be interconnected across the thickness of the graft wall ( Figure 2d ). The average fiber diam eter and pore area were measured by ImageJ and found to be 422 ± 33 nm and 10 ± 4 μm 2 , respectively. Additionally, the wall thickness of the graft tubes, as determined from SEM images, was found to increase proportionally with the electro spinning collecting time. The wall thicknesses of the TEVG fabricated at different electrospinning collecting times were as follows: 151 ± 27 μm (t = 60 min), 204 ± 18 μm (t = 90 min), 255 ± 18 μm (t = 120 min), 305 ± 15 μm (t = 150 min), and 348 ± 17 μm (t = 180 min).
Biomechanical Properties of Scaffolds
The tensile properties, suture retention strength, and burst pressure were measured on all PEU electrospun TEVG to ensure that they possess significant biomechanical proper ties to function as vascular grafts. The physical properties of the poly(1LEU10) electrospun grafts were summarized in Table 2 .
The tensile properties of the electrospun tube scaffolds were studied by uniaxial tensile testing of the whole graft using an Instron 5567 universal tensile testing machine. Using the stress-strain plot (Figure 3) , the ultimate tensile strength (UTS), elongation at break, and elastic modulus of type A PEU grafts (250 μm) were determined. The graft scaffolds showed averaged elastic modulus of 1.8 ± 0.1 MPa, ultimate tensile strength of 1.7 ± 0.2 MPa, and elongation at break of 598 ± 26%. Here, we noticed that the elastic modulus of the PEU grafts fell within the range of the native blood ves sels (0.16-12 MPa). [11, 66, 67] This is of great significance, since the close the mechanical properties of grafts come to that of native blood vessels, the less the chance of graft failure due to mechanical property mismatch. [10] Suture retention strength is essential to evaluate the material for resisting the tension during implantation and it [68] the electrospun PEU grafts showed more than adequate strength for suturing during implantation. Also, other previous works reported that the suture retention strength is generally accepted to be greater than 2.0 N. [69] Burst pressure identified as the maximum pressure that the scaffolds could endure before failure is a crucial factor to determine whether the scaffold material is strong enough to endure physiologic forces and avoid blood leakage. [68] In our study, the limitation of the burst pressure testing machine is 1000 mmHg. As the pressure inside the grafts with continuous water flow increased gradually until it reached the limitation Figure 3 . An engineering stress-strain plot of type A PEU whole TEVG (250 μm) under wet condition using uniaxial tensile testing. The tensile properties of the PEU grafts were measured using an Instron 3365 universal materials testing machine. The gauge length was 10 mm and the crosshead speed was set at 10 mm min −1 . The elastic modulus of the grafts, ultimate tensile stress (UTS), and elongation at break (%) were obtained from the stress-strain curve. Results presented are average values for six individual measurements (n = 6). The graft scaffolds showed averaged elastic modulus of 1.8 ± 0.1 MPa, ultimate tensile strength of 1.7 ± 0.2 MPa, and elongation at break of 598 ± 26%. of the machine, the PEU electrospun grafts did not break even after we held the pressure at 1000 mmHg for 30 min and no leakage was observed.
In Vitro Results
There is little evidence regarding the ability of PEUs to sup port vascular cell attachment and proliferation, which is a first requirement for their application in vascular tissue engi neering. In order to evaluate if the PEU materials are able to support the attachment and spreading of vascular cells, A10 smooth muscle cells (A10 SMCs) and human umbilical vein endothelial cells (HUVECs) were seeded on positive control glass coverslips and electrospun PEU covered glass coverslips, both of which are 2D substrates. After 48 h of culture, immuno histochemical labeling for Factin and DNA were used to iden tify the cellular morphology. As shown in Figure 5a , both A10 SMCs and HUVECs attached and spread on the 2D surface with significant, aligned Factin expression. Quantification of the cell areas revealed that cells contacting the electrospun con structs spread comparably with those cultured on control glass coverslips ( Figure S3 , Supporting Information). This likely means that cells put down focal adhesion contacts and spread on the PEU electrospun nanofibers similar to the way they nor mally would adhere and spread on glass coverslips. This result suggests that the PEU nanofibers are able to support vascular cell adhesion and spreading in vitro. Since cell adhesion and spreading are the first events that dictate the subsequent cel lular responses such as proliferation, migration, and matrix deposition, [29] it is important that the PEU nanofibers were able to promote these initial events.
The growth of vascular cells on the nanofibrous scaffolds is another critical issue for their clinical applications. The proliferation of A10 SMCs and HUVECs on electrospun PEU nanofiber in vitro can provide initial confirmation of the utility of the scaffolds. The growth profiles of A10 SMCs and HUVECs cultured on the positive control glass coverslips and electrospun PEU covered glass coverslips were measured over a 7 d time course. As shown in Figure 5b , the vascular cells continued to increase in number over the time interval exam ined on both positive controls and electrospun PEU at similar proliferation rates, indicating that the PEU nanofibers are able to support vascular cell proliferation without producing toxic effects for at least 7 d in vitro.
In Vivo Animal Study
Survival of the Animals
The survival rate of mice with poly(1LEU10) graft implanta tion at 24 h after surgery was 100%. The survival rate at 12 months postoperation was 80% (4/5). One mouse died at three months after graft implantation due to a thymus tumor (deter mined by necropsy) and was not graft related. No longterm graft related complications such as graft rupture or aneurysmal dilatation were observed.
Ultrasound and Micro-Computed Tomography (CT)
In vivo ultrasound was performed at 5 weeks, 9 weeks, and 12 months. All poly(1LEU10) grafts demonstrated luminal patency at each time point without evidence of aneurysmal dilatation or stenosis from the ultrasound results (Figure 6b,c) . However, the inner diameter of the lumen decreased from the 5 week time point to the 12 month time point postimplantation as a consequence of neovessel regeneration. MicroCT angiog raphy (Figure 7) showed that aneurysmal dilatation or stenosis was absent in poly(1LEU10) type A grafts 12 months after graft implantation, while all type B grafts showed occlusion.
Histological Assessment
Histological assessment was further performed on all harvested poly(1LEU10) grafts after 12 months to evaluate the neovessel remodeling process. Endothelial cells are the predominant cells in the lumen of the blood vessel walls and are required for the structural and functional integrity of the new blood vessel. In this study, the TEVG were harvested and stained for the pres ence of CD31 (a marker for endothelial cells). CD31 signatures lined in the lumen of type A grafts after graft implantation at 12 months. This result indicated confluent endothelium layers were formed in the type A graft lumen that can mimic native aorta (Figure 8b,e) . Smooth muscle cells were defined by the presence of alpha smooth muscle actin (aSMA) staining and were observed in the tunica media which infiltrated and replaced the poly(1LEU10) type A grafts (Figure 8c,f) varied in wall thickness while maintaining the same mate rial composition, elastic mechanical properties, and structure morphology, we did not expect to observe such vastly different results in the animal model study. Future work will include further exploration into the wall thickness and biomechanical effects by testing compliance properties of the two different graft types.
Conclusions
This paper described a cellfree small diameter (ID ≈ 1 mm) vas cular graft engineered from electrospun resorbable PEU. Long term performance in vivo of two types of PEU grafts of different wall thickness (type A: 250 μm; type B: 350 μm) were evaluated in an abdominal infrarenal aortic interposition mouse model over one year. Extensive tissue remodeling was observed in all type A grafts, which lead to the development of neovessels that mimics native arteries. However, the type B grafts experienced occlusion over the one year interval due to intimal hyperplasia. These results suggest the poly(ester urea) may be a promising material for cellfree tissue engineered small diameter vascular grafts, but further biomechanical investigations will be required to assess the effect of graft wall thickness on the longterm per formance of the grafts.
Experimental Section
Materials: Unless listed otherwise, all chemical solvents and reagents were purchased from Sigma-Aldrich or Alfa Aesar and used as received. Chloroform was dried with CaH 2 overnight and distilled before use. A-10 SMC cells (CRL-1476, ATCC, Rockville, MD) were maintained for less than 20 passages in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 units mL −1 penicillin, 100 μg mL −1 streptomycin, and 2 mmol L −1 l-glutamine (all from Invitrogen, Carlsbad, CA). HUVEC cells (C2517A, Lonza, Basel, Switzerland) were maintained for less than 20 passages in endothelial growth medium kit (EGM-2 BulletKit, CC-3156 and CC-4176, Lonza, Basel, Switzerland) supplemented with 100 units mL −1 penicillin (Invitrogen, Carlsbad, CA). Rhodamine phalloidin and DAPI (4′,6-diamidino-2-phenylindole) dyes were also from Invitrogen. Cytoskeleton stabilization (CS) buffer was prepared using 1,4-piperazinediethanesulfonic acid (PIPES, 0.1 m) (Fisher Scientific, Pittsburgh, PA), ethylene glycolbis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA, 1 × 10 −3 m) (Sigma Aldrich, St. Louis, MO), and 4% (w/v) polyethylene glycol (PEG, M w = 8000) (Fisher Scientific, Pittsburgh, PA) in distilled water. The solution was buffered using 1 m hydrochloric acid and 1 m sodium hydroxide solutions as required to obtain a pH of 6.9.
Instrumentation: 1 H and 13 C NMR spectra of the monomer and polymer were obtained on Varian NMRS 500 spectrometers. Chemical shifts were reported in parts per million (δ) and referenced to the chemical shifts of the residual solvent ( 1 H NMR, DMSO-d 6 (2.50 ppm); 13 C, DMSO-d 6 (39.50 ppm)). The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, br = broad singlet, m = multiplet. FTIR spectrum was recorded on a Shimadzu MIRacle 10 ATR-FTIR spectrometer. SEC analyses were performed using a TOSOH HLC-8320 gel permeation chromatograph using 10 × 10 −3 m LiBr in DMF as eluent at a flow rate of 0.8 mL min −1 . The column and detector temperatures were maintained at 50 °C. The molecular mass and mass distribution were calculated from a universal calibration based on polystyrene standards. The thermal stability of the polymer was measured using TGA (TA Q500) across a temperature range of 0-600 °C at a scanning rate of 20 °C min −1 under nitrogen. 5% decomposition temperature data was collected. The thermal transition of the polymer was studied by using DSC (TA Q2000) from −20 to 120 °C at a scanning rate of 20 °C min −1 . The glass transition temperature was determined as the midpoint in the second heating cycle of DSC.
Polymer Synthesis and Characterization: The poly(ester urea) monomer and polymer were prepared following previous methods, [61] as shown in 24 (m, 4H), 1.41-1.44 (m, 4H), 1.51-1.54 (t, 4H) 
The characterization data summary of polymer molecular mass and thermal properties is listed in Table 1 .
Graft Fabrication: Vascular grafts were fabricated by electrospinning using a 10 w% PEU solution in hexafluoroisopropanol (HFIP). The electrospinning setup included a syringe pump, a high voltage supply, and a rotating mandrel. A 10 kV positive voltage was applied to the polymer solution by the power supply. The polymer solution was drawn through a 23 gauge blunt tip needle at a constant flow rate of 1 mL h −1 . Polymer fibers were then collected on a grounded rotating mandrel mounted on a homemade stand. The collecting mandrel was a stainless steel rod with ≈1 mm diameter. The collecting mandrel was pre-coated with sugar solution. The distance between the syringe tip and the mandrel was set as 15 cm and the mandrel rotation rate was 100 rpm. To remove the graft from the mandrel, the graft together with the mandrel was soaked in deionized water for 1 h. When the thin layer of sugar was dissolved by water, the graft can be easily removed from the mandrel by gently pulling it from one direction. The obtained grafts were then freeze-dried and stored in clean glass vials for future use. Prior to implantation, the grafts were sterilized by ethylene oxide (ETO) for 24 h. Two types of PEU grafts with two different wall thicknesses were prepared for implantation (type A: 250 μm; type B: 350 μm).
Graft Characterization: The electrospun TEVG were characterized using FE-SEM (JSM-7401F, JEOL Ltd., Japan). Characterization included determining the average fiber diameter and average pore area. For each sample, ten SEM images were analyzed, and at least 50 fibers chosen randomly from across the image were measured manually on each image and quantified using ImageJ software (NIH USA, 2008). Pore areas were also measured by a subjective approximation of surface pores from the SEM images (at least 20 measurements per image). Results are given as mean ± standard deviation. For all of the measurements made from the SEM images, calibration of the ImageJ software was done with the scale bar on each image.
Biomechanical Evaluations: Tensile Properties: Uniaxial tensile testing of electrospun grafts was performed on 1 mm inner diameter tubular specimens from six different electrospun grafts using an Instron 5567 universal tensile testing machine. After soaking the specimens in PBS for 24 h at 37 °C, tensile properties were measured by clamping a 20 mm long graft in the tensile-testing machine and pulling the samples until failure. The gauge length was set as 10 mm, and the crosshead speed was set at 10 mm min −1 . Stress-strain data were reported using the Instron Bluehill software. The data were plotted using Origin 8.1 and the ultimate tensile strength, modulus, and strain at break were calculated. Results presented are average values for three individual measurements.
Suture Retention Strength: Suture retention testing was performed on six 1 mm inner diameter tubular specimens from six different electrospun grafts according to the procedure described in Section 8.8 of the American National Standards Institute (ANSI)/Association for the Advancement of Medical Instrumentation (AAMI) ANSI/ AAMI VP20:1994 entitled "Cardiovascular Implants-Vascular Graft Prostheses" [68] : After soaking the grafts in PBS for 24 h at 37 °C, one end of the graft was fixed to the stage clamp of the uniaxial tensile testing machine (Instron 5567, USA) and the other end was connected to another clamp using a loop of a common suture material (5-0 Prolene, Ethicon Inc.) placed 2 mm from the edge of the free end of the graft.
The gauge length was set as 20 mm, and the crosshead speed was set at 150 mm min −1 until the suture ripped or the graft failed. Suture retention strength, which was defined as fracture strength, was recorded in Newtons using the Instron Bluehill software.
Burst Pressure Strength: The burst pressure strength for the electrospun TEVG was measured by increasing the pressure within the tubular vascular graft until failure occurred (in this case, the pressure level reached the limitation of the machine before graft failed). Luer-lock needle adapters with matching size of the testing grafts were inserted and fixed by superglue to both ends of the grafts. A pressure transducer catheter which connected to computer was attached to one end of the grafts via the luer-lock needle adapters. A 100 mL pressure syringe was attached to the other end of the grafts. The pressure was gradually increased until reaching the limitation of the machine and the pressure change was recorded on computer.
Biological Activity Evaluations: For the cell culture studies, PEU nanofibers of identical dimensions were electrospun onto glass coverslips to form 2D structures. The PEU nanofiber covered glass coverslips were then placed into 12-well plates, sterilized by ethylene oxide for 24 h, and pre-soaked for 4 h in cell culture medium prior to cell seeding. Blank glass coverslips were used as control study. A-10 SMCs and HUVECs between passage 10 and 14 were used and seeded directly on the surface of the glass coverslips at a density of 2 × 10 4 per well. The cell-seeded coverslips were incubated for 4 h to allow cells to adhere to the nanofibers before adding additional cell culture medium to the culture plate. Samples of separate studies were all done in triplicate to assure reproducibility of the results. A-10 SMCs were cultured with DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. HUVECs were cultured with EGM-2 Bulletkit (Lonza) with basal medium, growth factors, cytokines, and supplements special for endothelial cells. Both cell types were cultured at 37 °C in a humidified incubator containing 5% CO 2 for scheduled time. The cell culture medium was changed every 48 h.
Cell Viability and Proliferation Study: Cell viability and proliferation were evaluated after 1, 3, and 7 d of cell seeding using PrestoBlue assay. Upon entering a living cell, PrestoBlue reagent is reduced from resazurin, a blue compound with no intrinsic fluorescent value, to resorufin which is red in color and highly fluorescent. Cell proliferation was assessed by the intensity of red color obtained, which was directly proportional to the metabolic activity of the cell population. At scheduled time points (day 1, 3, and 7), cell culture medium was removed. Cell seeded coverslips were transferred to empty 12-well culture plates and refilled by 1 mL of fresh cell medium containing 10% v/v of PrestoBlue. After 0.5-2 h of incubation at 37 °C, 3 × 100 μL of medium was taken from each well to a 96-well plate and analyzed for fluorescence measurement. The fluorescence intensity was measured on a Synergy MX plate reader from BioTek at an excitation wavelength of 560 nm and an emission wavelength of 590 nm. The observed fluorescence intensity was then converted to cell numbers according to established calibration curves.
Cell Attachment and Spreading Study: To study cell attachment and spreading on the scaffold material, A-10 SMCs and HUVECs (78 cell mm −2 ) were seeded directly on the PEU nanofiber covered glass coverslips in 12-well culture plates and cultured for 48 h before fixation. For immunohistochemical staining, cells were fixed using 3.7% paraformaldehyde in CS buffer for 10 min and then permeabilized with 0.5% TritonX-100 for 9 min. Excess formaldehyde was quenched with 0.05% sodium borohydride in PBS. 5% donkey serum in CS buffer was then added and the well plate was incubated at room temperature for 20 min to block the non-specific binding activity. The actin filaments of the cytoskeleton were stained with rhodamine phalloidin (1:200 dilution in PBS) for 1 h. After rinsing three times with PBS, the nucleus was stained with DAPI (1:1000 dilution in PBS) for 20 min and washed four times with PBS. Coverslips were mounted on microscope slides with mounting medium for fluorescence (Vector Laboratories Inc., Burlingame, CA) and sealed with nail enamel upon drying. Fluorescent pictures were taken using and inverted IX 81 microscope (Olympus, Center Valley, PA) with 10×, 20×, and 40× objectives.
Animal Study: All animals received humane care in compliance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. The Institutional Animal Care and Use Committee (IACUC) at Nationwide Children's Hospital approved the use of animals and all procedures described in this study. Eight-week old female SCID/ Bg mice were purchased from Taconic Biosciences (Hudson, NY).
Graft Implantation: Poly(1-LEU-10) grafts were implanted as infrarenal aortic interposition conduits using microsurgical technique (n = 5 for each type and time point). The mice were anesthetized using ketamine xylazine cocktail with ketoprofen as pre-anesthesia analgesic. The hair in the surgical area was removed by a razor and then disinfected by betadine and alcohol pads. A midline laparotomy incision from below the xyphoid to the suprapubic region was made, and a self-retaining retractor inserted. The intestines were wrapped in saline-moistened gauze and retracted. The infra-renal aorta and inferior vena cava were bluntly defined. Microsurgery was performed using an operating microscope with zoom magnification. The aorta was separated from the inferior vena cava and vascular control was obtained with microvascular clamps and then the infra-renal aorta was transected. A poly(1-LEU-10) aortic interposition graft was implanted with proximal and distal endto-end anastomoses using a sterile 10-0 monofilament suture on tapered needles. Any hemorrhage was controlled by applying topical absorbable sterile hemostatic agents (Surgicel). The intestines were returned to the abdominal cavity. The abdominal musculature and skin were closed in two layers using 6-0 prolene suture. The length of the procedure was 35 min. Motrin water was provided for 48 h after surgery. Animals were followed for 9 weeks and 12 months after implantation. Post-operatively, no drugs such as anti-platelet or anti-coagulant agents were used.
Ultrasound: Serial ultrasonography (Vevo Visualsonics 770; Visualsonics, Toronto, ON, Canada) was used to monitor grafts after implantation. Prior to ultrasonography, mice were anesthetized with 1.5% inhaled isoflurane. Graft luminal diameter was determined sonographically at the indicated time points after implantation and patency was determined by measuring flow velocity proximal and distal to the graft.
Contrast-Enhanced Micro-CT Angiography: Under anesthesia, in vivo micro-CT angiography was performed with the GE eXplore Locus in vivo micro-CT scanner (GE Healthcare, Milwaukee, WI, USA). Micro-CT data were acquired with an X-ray source of 70 kVp tube voltage, 32 mA tube current, 4 × 4 detector binning model, 16 ms exposure per frame, 70 gain, and 20 offset for contrast-enhanced CT acquisitions. 1 min prior to acquisition, animals were given an intra-jugular 0.3 cc bolus of Ultravist (370 mgI mL −1 , Bayer Healthcare, Wayne, NJ). A single frame of 220 projections for 42 s of continuous X-ray exposure was used. Volumetric micro-CT images were reconstructed in a 360 × 185 × 505 format with voxel dimensions of 98.4 × 98.4 × 98.4 μm 3 using a Feldkamp algorithm with calibrated Hounsfield units (HU).
Micro-CT data were transferred to the Advanced Workstation (version 4.4; GE Healthcare) for further reconstruction and quantitative analysis. Sites of anastomosis were approximated. Measurements of graft length, inner luminal diameter, and graft volume were performed. Similar measurements were performed on adjacent aortas in mice implanted with grafts as well as in controls having undergone sham operation.
Histology and Immunohistochemistry: Grafts harvested at 12 months were fixed in 4% paraformaldehyde (PFA) and embedded in paraffin. 5 μm thick sections were then stained using standardized technique for hematoxylin and eosin (H&E).
Identification of the endothelium and smooth muscle cells was done by immunohistochemical staining of the paraffin-imbedded explant sections with anti-CD 31 (1:50, Abcam), aSMA (Dako, Carpinteria, CA). Antibody binding for CD31 and aSMA was detected using biotinylated anti IgG (1:200, Vector, Burlingame, CA). This was followed by binding of streptavidin-horse radish peroxidase (HRP) and color development with 3,3-diaminobenzidine (DAB).
Statistical Analysis: Results are expressed as mean ± standard deviation. The statistical significance of differences among time points was analyzed using one-way ANOVA. A probability value of less than 0.05 was considered significant.
